Return to Today's science sparks archives

2010-10-01

Fig 5.  HT29 tumor sections showing blood perfusion, in vivo targeting of CAIX by 111In-DOTA-Fab-cG250 and endogenous CAIX expression at 24 hours pi.

Fig 5. HT29 tumor sections showing blood perfusion, in vivo targeting of CAIX by 111In-DOTA-Fab-cG250 and endogenous CAIX expression at 24 hours pi.
  • Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM

  • PLoS One. 2010 May 27;5(5):e10857.
Open Access button

2010-10-04

Fig 2B. ZIC1 immunofluorescence 8 d postinfection in the ZIC1 knockdown liposarcoma cells.

Fig 2B. ZIC1 immunofluorescence 8 d postinfection in the ZIC1 knockdown liposarcoma cells.
  • Brill E, Gobble R, Angeles C, Lagos-Quintana M, Crago A, Laxa B, Decarolis P, Zhang L, Antonescu C, Socci ND, Taylor BS, Sander C, Koff A, Singer S

  • Cancer Res. 2010 Sep 1;70(17):6891-901.

2010-10-05

Fig 5. siRNA-directed knockdown of Hsp72 abrogates enhanced viral replication.

Fig 5. siRNA-directed knockdown of Hsp72 abrogates enhanced viral replication.
  • Eisenberg DP, Carpenter SG, Adusumilli PS, Chan MK, Hendershott KJ, Yu Z, Fong Y

  • Surgery. 2010 Aug;148(2):325-34.

2010-10-06

Fig. 2. Genome rearrangement by non-allelic homologous recombination.

Fig. 2. Genome rearrangement by non-allelic homologous recombination.
  • Sasaki M, Lange J, Keeney S

  • Nat Rev Mol Cell Biol. 2010 Mar;11(3):182-95.

2010-10-07

Fig 4a. Pten +/− mouse medulloblastomas display increased angiogenesis.

Fig 4a. Pten +/− mouse medulloblastomas display increased angiogenesis.
  • Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL

  • PLoS One. 2010 May 26;5(5):e10849.

2010-10-08

Fig 1a. Array-CGH characterization of the primary and metastatic melanoma genomes.

Fig 1a. Array-CGH characterization of the primary and metastatic melanoma genomes.
  • Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L

  • PLoS One. 2010 May 24;5(5):e10770.

2010-10-11

Fig 1. The basic mechanism of HR involves processing a double-strand break to reveal a 3′-single-strand tail.

Fig 1. The basic mechanism of HR involves processing a double-strand break to reveal a 3′-single-strand tail.
  • Barker CA, Powell SN

  • Semin Radiat Oncol. 2010 Oct;20(4):267-273.e3.

2010-10-12

Fig 10a. DSETDB1-mediated DNA methylation mediates silencing of Rt1b{} and HeT-A retrotransposons in the developing wing.

Fig 10a. DSETDB1-mediated DNA methylation mediates silencing of Rt1b{} and HeT-A retrotransposons in the developing wing.
  • Gou D, Rubalcava M, Sauer S, Mora-Bermúdez F, Erdjument-Bromage H, Tempst P, Kremmer E, Sauer F

  • PLoS One. 2010 May 17;5(5):e10581.
Open Access button

2010-10-13

Fig 2. This chart illustrates the standardized variable importance (VIMP) of anatomic and nonanatomic cancer characteristics

Fig 2. This chart illustrates the standardized variable importance (VIMP) of anatomic and nonanatomic cancer characteristics
  • Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration

  • Cancer. 2010 Aug 15;116(16):3763-73.

2010-10-14

Fig 5. Processes regulated by Drosophila miR-bantam. The bantam miRNA controls a wide variety of processes.

Fig 5. Processes regulated by Drosophila miR-bantam. The bantam miRNA controls a wide variety of processes.
  • Smibert P, Lai EC

  • Semin Cell Dev Biol. 2010 Sep;21(7):745-53.

2010-10-15

Fig. 1. Computed tomography image of new mass in the lower pole of the left kidney

Fig. 1. Computed tomography image of new mass in the lower pole of the left kidney
  • Rich BS, McEvoy MP, La Quaglia MP

  • J Pediatr Surg. 2010 Sep;45(9):1883-6.

2010-10-18

Fig 5. Overall survival of patients stratified by clinical maximum standardized uptake value (SUVmax) cutoffs of <5, 5–10, or >10 (p <0.01).

Fig 5. Overall survival of patients stratified by clinical maximum standardized uptake value (SUVmax) cutoffs of <5, 5–10, or >10 (p <0.01).
  • Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, Fisher GA, Goodman KA, Koong AC, Chang DT

  • Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1420-5.

2010-10-19

Fig 2. The effect of age on freedom from biochemical failure (FFbF). The top curve represents the patients age ≤60 years, whereas the bottom curve represents those aged >60 years. There was no statistically significant difference between these two age groups with respect to FFbF (p = 0.071).

Fig 2. The effect of age on freedom from biochemical failure (FFbF). The top curve represents the patients age ≤60 years, whereas the bottom curve represents those aged >60 years. There was no statistically significant difference between these two age groups with respect to FFbF (p = 0.071).
  • Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG

  • Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1315-21.

2010-10-20

Fig 6. 
Implantation-delayed blastocysts lacking PDGFRα exhibit defects in the PrE and pluripotent epiblast (EPI) lineages. (Aa-Ch).

Fig 6. Implantation-delayed blastocysts lacking PDGFRα exhibit defects in the PrE and pluripotent epiblast (EPI) lineages. (Aa-Ch).
  • Artus J, Panthier JJ, Hadjantonakis AK

  • Development. 2010 Oct;137(20):3361-72.

2010-10-21

Fig 2.  TRIP13 is needed for completion of meiosis in males and females.

Fig 2. TRIP13 is needed for completion of meiosis in males and females.
  • Roig I, Dowdle JA, Toth A, de Rooij DG, Jasin M, Keeney S

  • PLoS Genet. 2010 Aug 12;6(8). pii: e1001062.
Open Access button

2010-10-22

Fig 1a. GEM is based on a simple model of gene regulation. A modulator interacts with a transcription factor to affect the expression of a target.

Fig 1a. GEM is based on a simple model of gene regulation. A modulator interacts with a transcription factor to affect the expression of a target.
  • Babur O, Demir E, Gönen M, Sander C, Dogrusoz U

  • Nucleic Acids Res. 2010 Sep 1;38(17):5648-56.
Open Access button

2010-10-25


Fig 1. The morphogenesis of Drosophila larval body wall muscles.

Fig 1. The morphogenesis of Drosophila larval body wall muscles.
  • Schejter ED, Baylies MK

  • Curr Opin Cell Biol. 2010 Oct;22(5):566-74.

2010-10-26

Fig 3. Bcl2L12 colocalizes with and binds to p53 in vitro and in vivo. (A) Deconvolution IF studies of untreated and ActD-treated U87MG (p53 wild-type) cells showed predominant colocalization of endogenous Bcl2L12 and p53 in the cell nucleus of ActD-treated cells.

Fig 3. Bcl2L12 colocalizes with and binds to p53 in vitro and in vivo. (A) Deconvolution IF studies of untreated and ActD-treated U87MG (p53 wild-type) cells showed predominant colocalization of endogenous Bcl2L12 and p53 in the cell nucleus of ActD-treated cells.
  • Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, Protopopov A, Chin L, Depinho RA

  • Genes Dev. 2010 Oct 1;24(19):2194-204.

2010-10-27

Fig 1. High variability of results for the enzyme-linked immunosorbent spot (ELISPOT) immune response assay.

Fig 1. High variability of results for the enzyme-linked immunosorbent spot (ELISPOT) immune response assay.
  • Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J

  • J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97.

2010-10-28

Fig 3. Histopathological features of glioblastomas with the PDGFRA mutant.

Fig 3. Histopathological features of glioblastomas with the PDGFRA mutant.
  • Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, Holland EC

  • Genes Dev. 2010 Oct 1;24(19):2205-18.

2010-10-29

Fig 1. Conventional renal cell carcinoma. Cells with abundant clear to finely vacuolated cytoplasm with centrally located round to slightly irregular nuclei and usually prominent nucleoli.

Fig 1. Conventional renal cell carcinoma. Cells with abundant clear to finely vacuolated cytoplasm with centrally located round to slightly irregular nuclei and usually prominent nucleoli.
  • Adeniran AJ, Al-Ahmadie H, Iyengar P, Reuter VE, Lin O

  • Diagn Cytopathol. 2010 Oct;38(10):710-5.

2010-11-01

Fig 2. Specific morphological features evaluated: (a) cribriform glands; (b) glomerulations; (c) signet-ring cells; (d) intraductal carcinoma; (e) mucinous fibroplasia; (f) mucinous features.

Fig 2. Specific morphological features evaluated: (a) cribriform glands; (b) glomerulations; (c) signet-ring cells; (d) intraductal carcinoma; (e) mucinous fibroplasia; (f) mucinous features.
  • Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, Satagopan JM, Scardino PT, Gerald WL, Reuter VE

  • Mod Pathol. 2010 Oct;23(10):1325-33.

2010-11-02

Fig 2. Probability of complication by age for patients undergoing PN (solid line) or RN (broken line) adjusted for ASA score, eGFR, tumor size, race and open vs laparoscopic procedure.

Fig 2. Probability of complication by age for patients undergoing PN (solid line) or RN (broken line) adjusted for ASA score, eGFR, tumor size, race and open vs laparoscopic procedure.
  • Lowrance WT, Yee DS, Savage C, Cronin AM, O'Brien MF, Donat SM, Vickers A, Russo P

  • J Urol. 2010 May;183(5):1725-30.

2010-11-03

Fig 1. Probability of cancer specific survival among patients with nonirradiated (blue) and irradiated (green) bladder cancer.

Fig 1. Probability of cancer specific survival among patients with nonirradiated (blue) and irradiated (green) bladder cancer.
  • Yee DS, Shariat SF, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, Herr HW, Dalbagni G, Sandhu JS

  • J Urol. 2010 May;183(5):1751-6.

2010-11-04

Fig 2. Bland-Altman plot of eGFR values.

Fig 2. Bland-Altman plot of eGFR values.
  • Shikanov S, Clark MA, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS Jr, Huang WC, Shalhav AL, Eggener SE

  • J Urol. 2010 Nov;184(5):1867-71.

2010-11-05

Fig 1. Toy representation of a linear partition of aCGH samples using large-margin techniques.

Fig 1. Toy representation of a linear partition of aCGH samples using large-margin techniques.
  • Rapaport F, Leslie C

  • PLoS One. 2010 Aug 12;5(8):e12028.
Open Access button

2010-11-08

Fig 1b. CT scan of the abdomen demonstrating reduced size of liver metastasis after treatment with rapamycin.

Fig 1b. CT scan of the abdomen demonstrating reduced size of liver metastasis after treatment with rapamycin.
  • Wessler JD, Steingart RM, Schwartz GK, Harvey BG, Schaffer W

  • Chest. 2010 Oct;138(4):991-3.

2010-11-09

Fig 1. Identification of (Ser)/(Thr) phosphorylation substrates in core cancer signaling pathways.

Fig 1. Identification of (Ser)/(Thr) phosphorylation substrates in core cancer signaling pathways.
  • Solit DB, Mellinghoff IK

  • Nat Biotechnol. 2010 Oct;28(10):1028-9.

2010-11-10

Fig 2. Kaplan-Meier estimates of overall survival (intent-to-treat population).

Fig 2. Kaplan-Meier estimates of overall survival (intent-to-treat population).
  • Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB

  • J Clin Oncol. 2010 Sep 20;28(27):4240-6.

2010-11-11

Fig 1. TFE3 fluorescence in situ hybridization on lesions using a TFE3 split probe combination consisting of a CY3-conjugated (red) probe located telomeric of the TFE3 gene and a FITC-conjugated (green) probe located centromeric of the TFE3 gene.

Fig 1. TFE3 fluorescence in situ hybridization on lesions using a TFE3 split probe combination consisting of a CY3-conjugated (red) probe located telomeric of the TFE3 gene and a FITC-conjugated (green) probe located centromeric of the TFE3 gene.
  • Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR, Weiss SW

  • Am J Surg Pathol. 2010 Oct;34(10):1395-406.

2010-11-12

Fig 1. Could ATRX Help to Convert G-Quadruplex DNA to Duplex DNA?

Fig 1. Could ATRX Help to Convert G-Quadruplex DNA to Duplex DNA?
  • Whitehouse I, Owen-Hughes T

  • Cell. 2010 Oct 29;143(3):335-6.

2010-11-15

Fig 3. Microarray epigenetic gene expression in primary and metastatic prostate cancers.

Fig 3. Microarray epigenetic gene expression in primary and metastatic prostate cancers.
  • Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource

  • Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22.

2010-11-16

Fig 3. Representative bioluminescence images show treatment effect of NDV(F3aa)-GFP over time.

Fig 3. Representative bioluminescence images show treatment effect of NDV(F3aa)-GFP over time.
  • Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y

  • Mol Cancer Ther. 2010 Oct;9(10):2761-9.

2010-11-17

Fig 2. A representative set of MALDI-TOF MS spectra showing Abltide released from magnetic beads before (A) and after (B) phosphorylation by c-Abl kinase.

Fig 2. A representative set of MALDI-TOF MS spectra showing Abltide released from magnetic beads before (A) and after (B) phosphorylation by c-Abl kinase.
  • Zhou G, Sylvester JE, Wu D, Veach DR, Kron SJ

  • Anal Biochem. 2011 Jan 1;408(1):5-11.

2010-11-18

Fig. 2. Detection rates according to biopsy location.

Fig. 2. Detection rates according to biopsy location.
  • Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, Shariat SF, Schröder FH, Scattoni V

  • Eur Urol. 2010 Sep 4.

2010-11-19

Fig 3. On-chip capture and immunofluorescent testing of captured tumor cells.

Fig 3. On-chip capture and immunofluorescent testing of captured tumor cells.
  • Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ

  • Clin Cancer Res. 2010 Oct 15;16(20):5011-8.

2010-11-22

Fig 3. DC undergo activation after ligation of TLR and prime CD4+ and CD8+ T cells.

Fig 3. DC undergo activation after ligation of TLR and prime CD4+ and CD8+ T cells.
  • Gnjatic S, Sawhney NB, Bhardwaj N

  • Cancer J. 2010 Jul-Aug;16(4):382-91.

2010-11-23

Fig. 1. Schematic overview of PSA and isoforms.

Fig. 1. Schematic overview of PSA and isoforms.
  • Bangma CH, van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman UH

  • Eur J Cancer. 2010 Nov;46(17):3109-19.

2010-11-24

Fig 7E-L. Proliferation and survival of the CNC is regulated by FN and integrin α5 at E8.5.

Fig 7E-L. Proliferation and survival of the CNC is regulated by FN and integrin α5 at E8.5.
  • Mittal A, Pulina M, Hou SY, Astrof S

  • Mech Dev. 2010 Sep-Dec;127(9-12):472-84.

2010-11-26

Figure 2. EUS-guided transgastric puncture of dilated MPD (patient 1). A, Diagram. B, EUS guidance during needle puncture. C, Pancreatogram.

Figure 2. EUS-guided transgastric puncture of dilated MPD (patient 1). A, Diagram. B, EUS guidance during needle puncture. C, Pancreatogram.
  • Ryou M, Mullady DK, Dimaio CJ, Swanson RS, Carr-Locke DL, Thompson CC

  • Gastrointest Endosc. 2010 Nov;72(5):1081-8.

2010-11-29

Figure 1. Knockdown of L3MBTL1 promotes the erythroid differentiation of human hematopoietic CD34+ progenitor cells.

Figure 1. Knockdown of L3MBTL1 promotes the erythroid differentiation of human hematopoietic CD34+ progenitor cells.
  • Perna F, Gurvich N, Hoya-Arias R, Abdel-Wahab O, Levine RL, Asai T, Voza F, Menendez S, Wang L, Liu F, Zhao X, Nimer SD

  • Blood. 2010 Oct 14;116(15):2812-21.

2010-11-30

Fig 1. Education and re-education of NK cells.

Fig 1. Education and re-education of NK cells.
  • Sun JC

  • J Exp Med. 2010 Sep 27;207(10):2049-52.

2010-12-01

Fig 6c. Ter119 expression in PU-H71–treated bone marrow is reduced in comparison with vehicle-treated JAK2V617F bone marrow, while there are no significant differences between either vehicle- or drug-treated MPLW515L marrow.

Fig 6c. Ter119 expression in PU-H71–treated bone marrow is reduced in comparison with vehicle-treated JAK2V617F bone marrow, while there are no significant differences between either vehicle- or drug-treated MPLW515L marrow.
  • Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL

  • J Clin Invest. 2010 Oct 1;120(10):3578-93.
Open Access button

2010-12-02

Fig 1. Example of creative techniques to blind radiographs of femoral neck fracture reduction, fixated with either a dynamic hip screw or 3 cannulated screws.

Fig 1. Example of creative techniques to blind radiographs of femoral neck fracture reduction, fixated with either a dynamic hip screw or 3 cannulated screws.
  • Karanicolas PJ, Farrokhyar F, Bhandari M

  • Can J Surg. 2010 Oct;53(5):345-8.
Open Access button

2010-12-03

Known high-penetrance genetic predisposition syndromes account for a minority of all familial colorectal cancer, leaving much of the genetic basis of CRC unexplained.

Known high-penetrance genetic predisposition syndromes account for a minority of all familial colorectal cancer, leaving much of the genetic basis of CRC unexplained.
  • Gallagher DJ, Smith JD, Offit K, Stadler ZK

  • Clin Colorectal Cancer. 2010 Oct;9(4):193-4.

2010-12-06

Crystal structure of CUGBP1 tandem RRM1/2 domains bound to 12-13 nucleotide RNAs.

Crystal structure of CUGBP1 tandem RRM1/2 domains bound to 12-13 nucleotide RNAs.
  • Teplova M, Song J, Gaw HY, Teplov A, Patel DJ

  • Structure. 2010 Oct 13;18(10):1364-77.

2010-12-07

FIG 2a. Fifty-four-year-old woman with a 1-cm classical papillary carcinoma showing microscopic extrathyroid extension (ETE). Low-power view of the main tumor mass (T) and the focus of ETE.

FIG 2a. Fifty-four-year-old woman with a 1-cm classical papillary carcinoma showing microscopic extrathyroid extension (ETE). Low-power view of the main tumor mass (T) and the focus of ETE.
  • Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J, Ghossein R

  • Thyroid. 2010 Oct;20(10):1085-93.

2010-12-08

Fig S12. DC101 enhances radiation-induced endothelial cell apoptosis. Representative cross sections of MCA/129 fibrosarcomas stained with both an endothelial cell specific Ab (anti-CD34, blue) and TUNEL (brown).

Fig S12. DC101 enhances radiation-induced endothelial cell apoptosis. Representative cross sections of MCA/129 fibrosarcomas stained with both an endothelial cell specific Ab (anti-CD34, blue) and TUNEL (brown).
  • Truman JP, García-Barros M, Kaag M, Hambardzumyan D, Stancevic B, Chan M, Fuks Z, Kolesnick R, Haimovitz-Friedman A

  • PLoS One. 2010 Aug 19;5(8): e12310.
Open Access button

2010-12-09

Fig 2. Incidence of febrile neutropenia.

Fig 2. Incidence of febrile neutropenia.
  • Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD

  • Bone Marrow Transplant. 2010 Oct;45(10):1522-7.

2010-12-10

Fig 1. Comparison of PET with F-FDG (A, B, C) and C-choline (D, E, F) in a patient with biochemical failure after external beam radiotherapy.

Fig 1. Comparison of PET with F-FDG (A, B, C) and C-choline (D, E, F) in a patient with biochemical failure after external beam radiotherapy.
  • Rioja J, Rodríguez-Fraile M, Lima-Favaretto R, Rincón-Mayans A, Peñuelas-Sánchez I, Zudaire-Bergera JJ, Parra RO

  • BJU Int. 2010 Dec;106(11):1578-93.

2010-12-13

Fig 1. Top panel shows set-up accuracy for partial breast irradiation isocenter placement after laser and skin mark positioning—DRR on the left and port film on the right. The isocenter is placed about 5 mm superiorly to the ideal position. The bottom panel shows the isocenter placement on the port film (right side) after repositioning the patient using either AlignRT or using the tumor bed clips, showing good concordance with the DRR.

Fig 1. Top panel shows set-up accuracy for partial breast irradiation isocenter placement after laser and skin mark positioning—DRR on the left and port film on the right. The isocenter is placed about 5 mm superiorly to the ideal position. The bottom panel shows the isocenter placement on the port film (right side) after repositioning the patient using either AlignRT or using the tumor bed clips, showing good concordance with the DRR.
  • Powell S

  • Breast J. 2010 Sep-Oct;16 Suppl 1:S34-8.

2010-12-14

Fig 1. Median Progression-Free Survival, Objective Response Rates, and Median Overall Survival.

Fig 1. Median Progression-Free Survival, Objective Response Rates, and Median Overall Survival.
  • Fornier M

  • Clin Breast Cancer. 2010 Oct 1;10(5):352-8.

2010-12-15

Fig 1. Comparison of ancestry composition of URD and CB transplant recipients and those without a graft. Greater than 50% of CB transplant recipients were non-European. Patients with African ancestry were the least likely to secure a suitable graft.

Fig 1. Comparison of ancestry composition of URD and CB transplant recipients and those without a graft. Greater than 50% of CB transplant recipients were non-European. Patients with African ancestry were the least likely to secure a suitable graft.
  • Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, Wells DS, Heller G, Papadopoulos EB, Scaradavou A, Young JW, van den Brink MR

  • Biol Blood Marrow Transplant. 2010 Nov;16(11):1541-8.

2010-12-16

Fig 1. Typical carcinoid. This tumor shows an organoid nesting pattern with a prominent vascular stroma.

Fig 1. Typical carcinoid. This tumor shows an organoid nesting pattern with a prominent vascular stroma.
  • Travis WD

  • Ann Oncol. 2010 Oct;21 Suppl 7:vii65-vii71.

2010-12-17

Fig 4. Mapping the physiologically relevant targets of a promiscuous drug.

Fig 4. Mapping the physiologically relevant targets of a promiscuous drug.
  • Burkard ME, Jallepalli PV

  • Biochim Biophys Acta. 2010 Dec;1806(2):251-7.

2010-12-20

Fig 5. Recruitment to PCNA by ubiquitin-like proteins.

Fig 5. Recruitment to PCNA by ubiquitin-like proteins.
  • Gareau JR, Lima CD

  • Nat Rev Mol Cell Biol. 2010 Dec;11(12):861-71.

2010-12-21

Fig 7. Determination of tumor location using ROI the same diameter as the tumor in the axial plane of the MPR.

Fig 7. Determination of tumor location using ROI the same diameter as the tumor in the axial plane of the MPR.
  • Deschamps F, Solomon SB, Thornton RH, Rao P, Hakime A, Kuoch V, de Baere T

  • Cardiovasc Intervent Radiol. 2010 Apr 14.

2010-12-22

Fig 4. IDH1/2 Mutations Are Mutually Exclusive with Mutations in TET2 in De Novo AML.

Fig 4. IDH1/2 Mutations Are Mutually Exclusive with Mutations in TET2 in De Novo AML.
  • Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A

  • Cancer Cell. 2010 Dec 14;18(6):553-67.

2010-12-23

Extra Centriolar Ana2 and DSas-6 Promote Centriole Overduplication and Increased Centriole Cohesion.

Extra Centriolar Ana2 and DSas-6 Promote Centriole Overduplication and Increased Centriole Cohesion.
  • Stevens NR, Roque H, Raff JW

  • Dev Cell. 2010 Dec 14;19(6):913-9.

2010-12-27

Fig 1. (a) Native chemical ligation. (b) Thio-FCMA ligation. (c) Challenge: thio-FCMA ligation in peptide couplings.

Fig 1. (a) Native chemical ligation. (b) Thio-FCMA ligation. (c) Challenge: thio-FCMA ligation in peptide couplings.
  • Wang P, Danishefsky SJ

  • J Am Chem Soc. 2010 Dec 1;132(47):17045-51.

2010-12-28

Fig 4. Antitumour activity of navitoclax. Waterfall plot of maximum percentage change in tumour size from baseline according to standard criteria[12] and [13] for 46 patients.

Fig 4. Antitumour activity of navitoclax. Waterfall plot of maximum percentage change in tumour size from baseline according to standard criteria[12] and [13] for 46 patients.
  • Wilson WH, O'Connor OA, Czuczman MS, Lacasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA

  • Lancet Oncol. 2010 Dec;11(12):1149-59.

2010-12-29

Fig 5. Proposed model of the inhibitory domain in the regulation of gamma-secretase for APP processing.

Fig 5. Proposed model of the inhibitory domain in the regulation of gamma-secretase for APP processing.
  • Tian Y, Crump CJ, Li YM

  • J Biol Chem. 2010 Oct 15;285(42):32549-56.

2010-12-30

Fig 2. Etv1 is expressed in the subtypes of ICCs susceptible to oncogenesis and is required for their development.

Fig 2. Etv1 is expressed in the subtypes of ICCs susceptible to oncogenesis and is required for their development.
  • Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL

  • Nature. 2010 Oct 14;467(7317):849-53.